Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Isotretinoin-Induced Severe Acne Flare Versus Acne Fulminans: A Challenging Case
Description
A dermatologist presented a challenging case of a previously healthy 14-year-old girl whose severe facial acne worsened dramatically during isotretinoin therapy, raising concern for either an isotretinoin-induced acne flare or acne fulminans. The patient had no truncal disease or systemic symptoms, and her lesions were nodulocystic rather than ulcerative or crusted, making the diagnosis unclear and not fitting classic acne fulminans patterns, which usually occur in males and often feature painful ulcerations and systemic illness. Initial management included lowering isotretinoin to the previously tolerated dose and adding prednisone, but the acne worsened further. After discussion, isotretinoin was ultimately stopped, prednisone continued, and hormonal/anti-inflammatory acne treatments such as oral contraceptives and spironolactone were added; she gradually improved, though with significant scarring. The speaker emphasized the lack of randomized evidence for managing these cases, discussed alternative options such as TNF-alpha inhibition, dapsone, and low-dose isotretinoin reintroduction in select patients, and highlighted the importance of close in-person monitoring because video visits may miss severity and progression.
View moreConclusions
- The case suggests that some severe isotretinoin-associated flares in adolescent girls may not fit classic acne fulminans and may represent a separate inflammatory acne phenotype.
- In ambiguous cases, management often requires shared decision-making rather than a single standard algorithm because the distinction between flare, progressing acne, and acne fulminans is clinically blurry.
- Reducing or stopping isotretinoin and adding systemic corticosteroids can help, but response may be incomplete and the condition may worsen if the inflammatory driver is not fully addressed.
- For refractory isotretinoin-triggered severe acne, hormonal therapy such as spironolactone and oral contraceptives may be useful, especially in female patients.
- TNF-alpha inhibitors like adalimumab or infliximab appear effective in refractory acne fulminans based on case series, but evidence is limited and there are no randomized trials.
- There is no universally accepted best treatment for isotretinoin-induced acne flares or acne fulminans, and available options are supported mostly by case series and expert consensus.
- Even when the active inflammation improves, scarring can be substantial and persistent, making prevention of progression the most important goal.
- Close in-person assessment is important because video visits can miss the severity and depth of inflammatory lesions that may be palpated only on exam.
- Low-dose isotretinoin may still be used in some patients after a flare has settled, but reintroduction should be cautious and individualized.
- Patients with strong family histories of severe scarring acne and prominent inflammatory disease may merit extra caution and possibly preventive strategies before isotretinoin escalation.
- Greywal et al., JAAD. 2017.
- Zouboulis et al., Exp Dermatol. 2020.
- Demircay et al., EJD. 2008.
- Dessinoti et al., JEADV. 2023.
- Journal der Deutschen Dermatologischen Gesellschaft. 2024;22:23–27.#10.1007/978-3-662-34443-9_1
- JEADV. 2024;38:e96-e98.